Gilead now own the rights to Sprint's preclinical oncology immunotherapy programme, which targets the novel cancer target, ...

Developed by UCL spinout Autolus, Aucatzyl will be launched imminently across England and Wales. A UK-developed cell therapy ...

At the 2025 Veeva Commercial Summit Europe, experts touted the benefits of AI but stressed the importance of data and ...

Novartis has received approval from the US Food and Drug Administration (FDA) for the Itvisma gene replacement therapy to ...

Made Scientific and Cellergy Therapeutics have formed a partnership to advance CLG-001 mitochondrial therapy towards in-human ...

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

Lilly breaking through the $1tn market cap ceiling comes as investors have increasingly turned to pharma stocks. The S&P 500 ...

AstraZeneca has announced a $2bn investment plan to expand its biomanufacturing presence in Frederick, Maryland, US.

In 2024, the FDA granted a record 63 designations to antibody drug conjugates (ADCs), nearly double the previous high of 35 ...

An FDA officer explains the agency’s compliance requirements for importing pharmaceuticals and biologics and processes.

Advances in large-volume injectors are enabling faster, more comfortable, at-home treatment. Patient-centric design, ...

OSR Company Vaximm has linked with investor BCM Europe (BCME) for a potential exclusive worldwide licence for Vaximm’s VXM01.